These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
265 related items for PubMed ID: 21405128
1. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent. Wang Y, Ai J, Wang Y, Chen Y, Wang L, Liu G, Geng M, Zhang A. J Med Chem; 2011 Apr 14; 54(7):2127-42. PubMed ID: 21405128 [Abstract] [Full Text] [Related]
2. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors. Zhai X, Bao G, Wang L, Cheng M, Zhao M, Zhao S, Zhou H, Gong P. Bioorg Med Chem; 2016 Mar 15; 24(6):1331-45. PubMed ID: 26897090 [Abstract] [Full Text] [Related]
3. Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors. Bode CM, Boezio AA, Albrecht BK, Bellon SF, Berry L, Broome MA, Choquette D, Dussault I, Lewis RT, Lin MH, Rex K, Whittington DA, Yang Y, Harmange JC. Bioorg Med Chem Lett; 2012 Jun 15; 22(12):4089-93. PubMed ID: 22595176 [Abstract] [Full Text] [Related]
4. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors. Li S, Zhao Y, Wang K, Gao Y, Han J, Cui B, Gong P. Bioorg Med Chem; 2013 Jun 01; 21(11):2843-55. PubMed ID: 23628470 [Abstract] [Full Text] [Related]
5. Synthesis and biological evaluation of 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazone scaffolds as selective c-Met inhibitors. Qi B, Tao H, Wu D, Bai J, Shi Y, Gong P. Arch Pharm (Weinheim); 2013 Aug 01; 346(8):596-609. PubMed ID: 23843304 [Abstract] [Full Text] [Related]
6. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation. Chen D, Wang Y, Ma Y, Xiong B, Ai J, Chen Y, Geng M, Shen J. ChemMedChem; 2012 Jun 01; 7(6):1057-70. PubMed ID: 22581753 [Abstract] [Full Text] [Related]
7. Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents. Tang Q, Zhao Y, Du X, Chong L, Gong P, Guo C. Eur J Med Chem; 2013 Nov 01; 69():77-89. PubMed ID: 24012712 [Abstract] [Full Text] [Related]
8. Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors. Liu Z, Wang R, Guo R, Hu J, Li R, Zhao Y, Gong P. Bioorg Med Chem; 2014 Jul 15; 22(14):3642-53. PubMed ID: 24882675 [Abstract] [Full Text] [Related]
9. Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors. Tang Q, Zhang G, Du X, Zhu W, Li R, Lin H, Li P, Cheng M, Gong P, Zhao Y. Bioorg Med Chem; 2014 Feb 15; 22(4):1236-49. PubMed ID: 24485123 [Abstract] [Full Text] [Related]
10. Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors. Qi B, Mi B, Zhai X, Xu Z, Zhang X, Tian Z, Gong P. Bioorg Med Chem; 2013 Sep 01; 21(17):5246-60. PubMed ID: 23838381 [Abstract] [Full Text] [Related]
11. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors. Williams DK, Chen XT, Tarby C, Kaltenbach R, Cai ZW, Tokarski JS, An Y, Sack JS, Wautlet B, Gullo-Brown J, Henley BJ, Jeyaseelan R, Kellar K, Manne V, Trainor GL, Lombardo LJ, Fargnoli J, Borzilleri RM. Bioorg Med Chem Lett; 2010 May 01; 20(9):2998-3002. PubMed ID: 20382527 [Abstract] [Full Text] [Related]
12. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H, Jewell JP, Kariv I, Katz JD, Kunii K, Lu W, Lutterbach BA, Paweletz CP, Qu X, Reilly JF, Szewczak AA, Zeng Q, Kohl NE, Dinsmore CJ. Cancer Res; 2010 Feb 15; 70(4):1524-33. PubMed ID: 20145145 [Abstract] [Full Text] [Related]
13. Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold. Zhao A, Gao X, Wang Y, Ai J, Wang Y, Chen Y, Geng M, Zhang A. Bioorg Med Chem; 2011 Jul 01; 19(13):3906-18. PubMed ID: 21665484 [Abstract] [Full Text] [Related]
19. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. Mannion M, Raeppel S, Claridge S, Zhou N, Saavedra O, Isakovic L, Zhan L, Gaudette F, Raeppel F, Déziel R, Beaulieu N, Nguyen H, Chute I, Beaulieu C, Dupont I, Robert MF, Lefebvre S, Dubay M, Rahil J, Wang J, Ste-Croix H, Robert Macleod A, Besterman JM, Vaisburg A. Bioorg Med Chem Lett; 2009 Dec 01; 19(23):6552-6. PubMed ID: 19854051 [Abstract] [Full Text] [Related]
20. N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases. Saavedra O, Claridge S, Zhan L, Raeppel F, Granger MC, Raeppel S, Mannion M, Gaudette F, Zhou N, Isakovic L, Bernstein N, Déziel R, Nguyen H, Beaulieu N, Beaulieu C, Dupont I, Wang J, Macleod AR, Besterman JM, Vaisburg A. Bioorg Med Chem Lett; 2009 Dec 15; 19(24):6836-9. PubMed ID: 19896842 [Abstract] [Full Text] [Related] Page: [Next] [New Search]